Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1246-1251

  Kersemaekers, Wendy M ^a   Van Iersel, Thijs ^a   Nassander, Ulla ^a   O'Mara, Edward ^b   Waskin, Hetty ^c   Caceres, Maria ^c   Van Iersela, Marlou L P S ^a,d  

^a NV ORGANON   (Netherlands)

^b CELGENE CORPORATION   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Global Scientific Affairs EDS PRA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RHINOPHARYNGITIS; SINGLE DRUG DOSE; THROMBOPHLEBITIS; ADOLESCENT; ADULT; AGED; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TRIAZOLES; YOUNG ADULT;

EID: 84921918086     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04223-14     Document Type: Article

References (14)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359. http://dx.doi.org/10.1056/NEJMoa061094.
2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335-347. http://dx.doi.org/10.1056/NEJMoa061098.
3. Keating GM. 2005. Posaconazole. Drugs 65:1553-1567.
4. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44: 2-12. http: //dx.doi.org/10.1086/508774.
5. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. 2006. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy, and other conditions. Clin Infect Dis 42:1398-1403. http://dx.doi.org/10.1086/503425.
6. Merck & Co., Inc. 2014. Noxafil (posaconazole) injection, delayed release tablets, and oral suspension. Prescribing information. Merck & Co., Inc., Whitehouse Station, NJ. http://www.merck.com/product/usa/pi-circulars/n /noxafil/noxafil-pi.pdf.
7. Merck Sharp & Dohme Limited. 2012. Noxafil (posaconazole) oral suspension. Prescribing information. Merck Sharp & Dohme Limited, Hertfordshire, United Kingdom.
8. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218-222. http://dx.doi.org /10.1046/j.1365-2125.2003.01977.x.
9. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
10. Krishna G, Ma L, Martinho M, O'Mara E. 2012. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 56: 4196 - 4201. http://dx.doi.org/10.1128/AAC .00222-12.
11. Pille S, Bohmer D. 1998. Options for artificial nutrition of cancer patients. Strahlenther Onkol 174(Suppl 3):52-55.
12. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B,Rosenberg MA, Saltzman MA. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 50:1881-1883. http: //dx.doi.org/10.1128/AAC.50.5.1881-1883.2006.
13. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 43:228-236. http://dx.doi.org/10 .1016/j.jpba.2006.06.011.
14. Soifer NE, Borzak S, Edlin BR, Weinstein RA. 1998. Prevention of peripheral venous catheter complications with an intravenous therapy team, a randomized controlled trial. Arch Intern Med 158:473-477. http: //dx.doi.org/10.1001/archinte.158.5.473.